Francesca Romana Mauro | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort	HEMATOLOGICAL ONCOLOGY	2024
Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas	HEMATOLOGICAL ONCOLOGY	2023
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling	BRITISH JOURNAL OF HAEMATOLOGY	2023
Pre‐exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents	BRITISH JOURNAL OF HAEMATOLOGY	2023
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	CANCERS	2023
Long‐term benefit of IGHV mutated patients in a real‐life multicenter cohort of FCR‐treated chronic lymphocytic leukemia	HEMATOLOGICAL ONCOLOGY	2023
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia	HAEMATOLOGICA	2022
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study	CANCERS	2022
Discrasie plasmacellulari	Ematologia Smart	2022
Linfoadenomegalie e linfomi	Ematologia Smart	2022
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement	HEMATOLOGICAL ONCOLOGY	2022
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement	HEMATOLOGICAL ONCOLOGY	2022
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model	AMERICAN JOURNAL OF HEMATOLOGY	2022
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. a retrospective multicentric gimema study	HAEMATOLOGICA	2022
Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response	LEUKEMIA & LYMPHOMA	2022
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)	LEUKEMIA	2021
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab	HAEMATOLOGICA	2021
TH2/TH1 shift under Ibrutinib treatment in chronic lymphocytic leukemia	FRONTIERS IN ONCOLOGY	2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases	AMERICAN JOURNAL OF HEMATOLOGY	2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	AMERICAN JOURNAL OF HEMATOLOGY	2021

Progetti di Ricerca

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS (DOACS) OR OTHER ANTICOAGULANT/ANTIAGGREGANT TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB: A MULTICENTER, REAL WORLD, OBSERVATIONAL STUDY.
CLINICAL AND SEROLOGICAL RESPONSE TO THE PNEUMOCOCCAL VACCINATION AFTER CHEMOIMMUNOTHERAPY OR ON KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Severe infections and pneumonia in relapsed/ refractory (R/R) patients with chronic lymphocytic leukemia (CLL) treated in the real world with bendamustine and rituximab (BR) chemoimmunotherapy or the kinase inhibitors (KIs) ibrutinib or idelalisib.
BCR PATHWAY AND BCL-2 INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED IN THE CLINICAL PRACTICE: OUTCOMES AND REASONS FOR TREATMENT DISCONTINUATION. A REAL WORLD OBSERVATIONAL STUDY